Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to2018Published: November 2011No. of Pages: 105...
- The late stage pipeline has molecules which would affect progression of HF, known asrenin inhibitor, Angiotensin recepto...
2 Heart Failure (HF) Therapeutics: Executive Summary 92.1 The HF Therapeutics Market Shows Significant Growth Until 2018 9...
6.1 Overview 616.2 Strategic Pipeline Assessment 616.3 HF Therapeutics Pipeline – Pipeline by Phases of Development 626.3....
11.5 Disclaimer 10411.6 Bibliography 105About Us:ReportsnReports is an online library of over 100,000+ market research rep...
Upcoming SlideShare
Loading in …5
×

ReportsnReports - Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

352 views

Published on

The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
352
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ReportsnReports - Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

  1. 1. Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to2018Published: November 2011No. of Pages: 105Price: $ 3500GlobalData, the Industry analysis specialist, has released its new report, “Heart Failure (HF)Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is anessential source of information on the global Heart Failure therapeutics market, andprovides analysis of a number of key areas. The report identifies the key trends shaping anddriving the global Heart Failure therapeutics market and provides insights into the currentcompetitive landscape and emerging companies expected to significantly alter the marketpositioning of current market leaders. Most importantly, the report provides valuableinsights into the pipeline products within the global Heart Failure sector. This report is builtusing data and information sourced from proprietary databases, primary and secondaryresearch and in-house analysis by GlobalData’s team of industry experts.The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grewat a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010.GlobalData analysis suggests that the global HF therapeutics market will grow at a highCAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will beprimarily attributed due to the expected launch of novel, therapies relaxin and LCZ696during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in2015. An increase in the treatment seeking population due to an increase in the lifeexpectancy and increasing awareness leading to diagnosis at an early stage will also drivethe HF therapeutics market. Apart from these the HF therapeutics market will be driven bythe increases in aging population which are more susceptible towards Acute Heart Failure(AHF). The current competition in the HF therapeutics market is weak, primarily dominatedby generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace(ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded productwhich are expected to lose patents in 2012 and 2014 respectively.ScopeThe report provides information on the key drivers and challenges of the Heart Failuretherapeutics market. Its scope includes -- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan)Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.
  2. 2. - The late stage pipeline has molecules which would affect progression of HF, known asrenin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acutecase of heart failure. The other promising drugs in the HF developmental pipeline in termsof mechanism of action include a stem cell therapy, angiotensin converting enzymeinhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-likepeptide 1 agonist.- Analysis of the current and future competition in the key countries of the Heart Failuretherapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics,and GlaxoSmithKline are the key players, they are key market players, is covered in thissection.- Insightful review of the key industry drivers, restraints and challenges. Each trend isindependently researched to provide a qualitative analysis of its implications.- Key topics covered include strategic competitor assessment, market characterization,unmet needs and the implications for the Heart Failure therapeutics market.- Analysis of key recent licensing and partnership agreements in Heart Failure therapeuticsmarket.Reasons to buyThe report will enhance your decision making capability. It will allow you to -- Develop and design in-licensing and out-licensing strategies through a review of pipelineproducts and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the globalHeart Failure therapeutics market.- Increase revenue through an understanding of the key trends, innovative products andtechnologies, market segments and companies likely to affect the global Heart Failuretherapeutics market in the future.- Formulate effective sales and marketing strategies by understanding the competitivelandscape and analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effectivecounter-strategies to gain a competitive advantage.- Organize sales and marketing efforts by identifying the market categories and segmentsthat present maximum opportunities for consolidations, investments and strategicpartnerships.- What’s the next big thing in the global Heart Failure therapeutics market landscape? –Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 61.2 List of Figures 7
  3. 3. 2 Heart Failure (HF) Therapeutics: Executive Summary 92.1 The HF Therapeutics Market Shows Significant Growth Until 2018 92.2 Current HF Therapeutics Market is Weak and is Dominated by Generics 102.3 Strong Pipeline Candidates Expected to Enter the Market, To Provide Better TreatmentOption 112.4 Unmet Need Remains Unaddressed 113 Heart Failure (HF) Therapeutics: Introduction 133.1 Overview 133.2 Etiology 143.3 Pathophysiology 173.4 Epidemiology & Prognosis 193.5 Symptoms 193.6 Diagnosis 203.7 Treatment and Management Pattern 273.7.1 Pharmacological Therapies 273.7.2 Goals of treatment of the patients with HF 283.8 GlobalData Report Guidance 314 HF Therapeutics: Market Characterization 324.1 HF Therapeutics Market Size (2005-2010) – Global 324.2 HF Therapeutics Market Forecast (2010-2018) – Global 334.3 HF Therapeutics Market Size (2005-2010): The US 344.4 HF Therapeutics Market Forecast (2010-2018): The US 364.5 HF Therapeutics Market (2005-2010): France 374.6 HF Therapeutics Market Forecast (2010-2018): France 374.7 HF Therapeutics Market (2005-2010): Germany 384.8 HF Therapeutics Market Forecast (2010-2018): Germany 394.9 HF Therapeutics Market (2005-2010): Italy 404.10 HF Therapeutics Market Forecast (2010-2018): Italy 414.11 HF Therapeutics Market (2005-2010): Spain 424.12 HF Therapeutics Market Forecast (2010-2018): Spain 434.13 HF Therapeutics Market (2005-2010): The UK 444.14 HF Therapeutics Market Forecast (2010-2018): The UK 454.15 HF Therapeutics Market (2005-2010): Japan 464.16 HF Therapeutics Market Forecast (2010-2018): Japan 474.17 Drivers and Barriers for the HF Therapeutics Market 494.17.1 Drivers for the HF Therapeutics Market 494.17.2 Barriers for the HF Therapeutics Market 494.18 Opportunity and Unmet Need Analysis 504.19 Key Takeaway 515 HF Therapeutics: Competitive Assessment 525.1 Overview 525.2 Strategic Competitor Assessment 525.3 Product Profile for the Major Marketed Products in the HF Therapeutics Market 545.3.1 Natrecor (nesiritide) 545.3.2 Primacor (milrinone lactate) 555.3.3 Coreg (Carvedilol) 565.3.4 Altace (ramipril) 575.3.5 Diovan (Valsartan) 585.4 Key Takeaway 606 HF Therapeutics: Pipeline Assessment 61
  4. 4. 6.1 Overview 616.2 Strategic Pipeline Assessment 616.3 HF Therapeutics Pipeline – Pipeline by Phases of Development 626.3.1 HF Therapeutics – Phase III Pipeline 626.3.2 HF Therapeutics – Phase II Pipeline 636.3.3 HF Therapeutics – Phase I Pipeline 636.3.4 HF Therapeutics – Preclinical Pipeline 646.3.5 HF Therapeutics – Discovery Pipeline 646.4 HF Therapeutics Market – Clinical Pipeline by Mechanism of Action 646.5 Technology Trends Analytical Framework 656.6 HF Therapeutics – Promising Drugs Under Clinical Development 676.7 Molecule Profile for Promising Drugs Under Clinical Development 686.7.1 Relaxin (RLX030) 686.7.2 LCZ696 696.7.3 Lixivaptan 696.7.4 Tekturna/Rasilez (aliskiren) 706.8 Key Takeaway 717 HF Therapeutics: Clinical Trials Mapping 727.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 727.2 Clinical Trials by Phase 737.3 Clinical Trials by Trial Status 747.4 Clinical Trials by Overall Sponsors 757.5 Prominent Sponsors 767.6 Key Companies Participating in Therapeutics Clinical Trials 778 HF Therapeutics: Stategic Assessment 798.1 Key Events Impacting the Future Market 798.2 HF Therapeutics: Implications for Future Market Competition 809 HF Therapeutics: Future Players 829.1 Introduction 829.2 Company Profiles 839.2.1 Novartis AG. 839.2.2 Amgen Inc. 859.2.3 Cardiokine, Inc 879.2.4 Bayer AG. 889.2.5 Nile Therapeutics, Inc.. 909.2.6 Cardioxyl Pharmaceuticals, Inc 919.2.7 Cytokinetics, Inc 929.2.8 GlaxoSmithKline plc 949.2.9 Trevena, Inc. 9510 HF Therapeutics: Licensing and Partnership Deals 9711 HF Therapeutics: Appendix 9811.1 Market Definitions 9811.2 Acronyms 9811.3 Research Methodologyy 9911.3.1 Coverage 9911.3.2 Secondary Research 10011.3.3 Forecasting 10011.3.4 Primary Research 10311.3.5 Expert Panel Validation 10411.4 Contact Us 104
  5. 5. 11.5 Disclaimer 10411.6 Bibliography 105About Us:ReportsnReports is an online library of over 100,000+ market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog

×